

Three-Component Synthesis of Enaminones via Ketene Cyclization

Hajime Seki and Gunda I. Georg*

Department of Chemistry, Department of Medicinal Chemistry, Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414

Supporting information

1. General methods	S2
2. General procedure for the preparation of amino diazoketones	S2
1-(Benzylamino)-3-diazopropan-2-one (3a)	S2
1-Diazo-3-(ethylamino)propan-2-one (3b)	S2
1-Diazo-3-(propylamino)propan-2-one (3c)	S2
1-(Allylamino)-3-diazopropan-2-one (3d)	S3
1-(Butylamino)-3-diazopropan-2-one (3e)	S3
1-((Cyclohexylmethyl)amino)-3-diazopropan-2-one (3f)	S3
(S)-1-Diazo-3-((1-phenylethyl)amino)propan-2-one (3g)	S3
1-((2-(1 <i>H</i> -Indol-3-yl)ethyl)amino)-3-diazopropan-2-one (3h)	S3
3. General procedure for the synthesis of enaminones	S3
Ethyl 1-Ethyl-4-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate (2b)	S4
Ethyl 4-Oxo-1-propyl-1,4,5,6-tetrahydropyridine-3-carboxylate(2c)	S4
Ethyl 1-Allyl-4-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate (2d)	S4
Ethyl 1-Butyl-4-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate (2e)	S4
Ethyl 1-(Cyclohexylmethyl)-4-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate (2f)	S5
Diethyl 1-Ethyl-4-oxo-1,4,5,6-tetrahydropyridine-2,3-dicarboxylate (4b)	S5
Diethyl 4-Oxo-1-propyl-1,4,5,6-tetrahydropyridine-2,3-dicarboxylate (4c)	S5
Diethyl 1-Allyl-4-oxo-1,4,5,6-tetrahydropyridine-2,3-dicarboxylate (4d)	S5
Diethyl 1-Butyl-4-oxo-1,4,5,6-tetrahydropyridine-2,3-dicarboxylate (4e)	S6
Diethyl 1-(Cyclohexylmethyl)-4-oxo-1,4,5,6-tetrahydropyridine-2,3-dicarboxylate (4f)	S6
5-Acetyl-1-ethyl-2,3-dihydropyridin-4(1 <i>H</i>)-one (5b)	S6
5-Acetyl-1-propyl-2,3-dihydropyridin-4(1 <i>H</i>)-one (5c)	S6
5-Acetyl-1-allyl-2,3-dihydropyridin-4(1 <i>H</i>)-one (5d)	S7
5-Acetyl-1-butyl-2,3-dihydropyridin-4(1 <i>H</i>)-one (5e)	S7
5-Acetyl-1-(cyclohexylmethyl)-2,3-dihydropyridin-4(1 <i>H</i>)-one (5f)	S7
5-Benzoyl-1-ethyl-2,3-dihydropyridin-4(1 <i>H</i>)-one (6b)	S7
1-Allyl-5-benzoyl-2,3-dihydropyridin-4(1 <i>H</i>)-one (6c)	S8
5-Benzoyl-1-(cyclohexylmethyl)-2,3-dihydropyridin-4(1 <i>H</i>)-one (6d)	S8
(S)-Ethyl 4-Oxo-1-(1-phenylethyl)-1,4,5,6-tetrahydropyridine-3-carboxylate (7a)	S8
(S)-Diethyl 4-Oxo-1-(1-phenylethyl)-1,4,5,6-tetrahydropyridine-2,3-dicarboxylate (7b)	S8
(S)-5-Acetyl-1-(1-phenylethyl)-2,3-dihydropyridin-4(1 <i>H</i>)-one (7c)	S9
(S)-5-Benzoyl-1-(1-phenylethyl)-2,3-dihydropyridin-4(1 <i>H</i>)-one (7d)	S9
Ethyl 1-(2-(1 <i>H</i> -Indol-3-yl)ethyl)-4-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate (8a)	S9
Diethyl 1-(2-(1 <i>H</i> -Indol-3-yl)ethyl)-4-oxo-1,4,5,6-tetrahydropyridine-2,3-dicarboxylate (8b)	S9
1-(2-(1 <i>H</i> -Indol-3-yl)ethyl)-5-acetyl-2,3-dihydropyridin-4(1 <i>H</i>)-one (8c)	S10
4. References and notes	S10
5. ¹H and ¹³C NMR spectra for all new compounds	S11

1. General methods


All reactions were performed in oven-dried glassware. Dichloroethane was distilled from CaH₂, and CH₂Cl₂ was dried before use over an activated alumina column. All reagents were used as received. The methods for analysis are as following.

- 1) All diazoketones and enaminones were UV-active on TLC, and were also detectible with ninhydrine and KMnO₄ solutions.
- 2) ¹H NMR data were recorded at 400 MHz spectrometer and ¹³C NMR data at 100 MHz. Chemical shifts are shown as ppm values relative to internal CHCl₃ (δ 7.26 for ¹H, δ 77.16 for ¹³C).
- 3) Melting points are uncorrected.
- 4) Optical rotation was measured at 23 °C.


2. General procedure for the preparation of amino diazoketones

Synthesis of amino diazoketones 3a-3g: To a solution of the amine (10 mmol, 4 equiv) in dichloroethane (9 mL), bromo diazoacetone (2.5 mmol) in dichloroethane (1 mL) was added dropwise.¹ The reaction mixture was heated to 50 °C for 3 h, then washed with aq. NaHCO₃ and brine, dried over MgSO₄ and concentrated *in vacuo*. The crude mixture was subjected to column chromatography (MeOH/CH₂Cl₂), affording the amino diazoketones as yellow oils.


Synthesis of amino diazoketone 3h: Bromo diazoacetone (2.5 mmol) and tryptamine hydrochloride (5 mmol, 2 equiv) were dissolved in MeONa/MeOH (0.5 M, 10mL). The solution was heated at 50 °C for 3 h, concentrated *in vacuo*, and re-dissolved in CH₂Cl₂. This organic solution was washed with aq. NaHCO₃ and brine, dried over MgSO₄ and again concentrated *in vacuo*. The crude mixture was subjected to column chromatography (NH₄OH/MeOH/CH₂Cl₂), affording amino diazoketone **8** as a yellow oil.




1-(Benzylamino)-3-diazopropan-2-one (3a), Yellow oil (87%); ¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.21 (m, 5H), 5.63 (s, 1H), 3.79 (s, 2H), 3.40 (s, 2H), 1.96 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 194.8, 139.6, 128.6, 128.3, 127.4, 56.3, 53.7, 53.1; IR (neat, cm⁻¹): 1143, 1343, 1638, 2105; HRMS (ESI) calcd for C₁₀H₁₂N₃O (M + H)⁺ 190.0980, found 190.0981.




1-Diazo-3-(ethylamino)propan-2-one (3b), Yellow oil (65%); ¹H NMR (400 MHz, CDCl₃) δ 5.63 (s, 1H), 3.38 (s, 2H), 2.63 (q, *J* = 7.1 Hz, 2H), 1.60 (s, 1H), 1.10 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 195.2, 57.1, 52.9, 44.3, 15.4; IR (neat, cm⁻¹): 1139, 1352, 1635, 2106, 2968; HRMS (ESI) calcd for C₅H₁₀N₃O (M + H)⁺ 128.0824, found 128.0817.




1-Diazo-3-(propylamino)propan-2-one (3c), Yellow oil (63%); ¹H NMR (400 MHz, CDCl₃) δ 5.65 (s, 1H), 3.38 (s, 2H), 2.55 (t, *J* = 7.1 Hz, 2H), 1.60 (s, 1H), 1.60 – 1.41 (m, 2H), 0.92 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 195.4, 57.3, 52.9, 52.0, 23.4, 11.8; IR (neat, cm⁻¹): 1139, 1343, 1637, 2104, 2960; HRMS (ESI) calcd for C₆H₁₂N₃O (M + H)⁺ 142.0980, found 142.0979.




1-(Allylamino)-3-diazopropan-2-one (3d). Yellow oil (72%); ^1H NMR (400 MHz, CDCl_3) δ 5.89 (m, 1H), 5.63 (s, 1H), 5.26 – 5.07 (m, 2H), 3.39 (s, 2H), 3.24 (d, J = 5.9 Hz, 2H), 1.71 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 195.0, 136.3, 116.7, 56.2, 53.1, 52.2; IR (neat, cm^{-1}): 923, 1143, 1344, 1638, 2105, 3080; HRMS (ESI) calcd for $\text{C}_6\text{H}_{10}\text{N}_3\text{O}$ ($\text{M} + \text{H}$) $^+$ 140.0824, found 140.0811.




1-(Butylamino)-3-diazopropan-2-one (3e). Yellow oil (80%); ^1H NMR (400 MHz, CDCl_3) δ 5.64 (s, 1H), 3.38 (s, 2H), 2.58 (t, J = 7.1 Hz, 2H), 1.78 (s, 1H), 1.46 (m, 2H), 1.35 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 195.3, 57.3, 52.9, 49.9, 32.3, 20.5, 14.1; IR (neat, cm^{-1}): 927, 1141, 1344, 1639, 2105, 2930; HRMS (ESI) calcd for $\text{C}_7\text{H}_{14}\text{N}_3\text{O}$ ($\text{M} + \text{H}$) $^+$ 156.1137, found 156.1132.



1-((Cyclohexylmethyl)amino)-3-diazopropan-2-one (3f). Yellow oil (81%); ^1H NMR (400 MHz, CDCl_3) δ 5.67 (s, 1H), 3.36 (s, 2H), 2.41 (d, J = 6.6 Hz, 2H), 1.78 – 1.55 (m, 6H), 1.41 (m, 1H), 1.29 – 1.08 (m, 3H), 0.98 – 0.84 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 195.7, 57.5, 56.9, 52.9, 38.3, 31.5, 26.8, 26.2; IR (neat, cm^{-1}): 1140, 1340, 1638, 2102, 2923; HRMS (ESI) calcd for $\text{C}_{10}\text{H}_{18}\text{N}_3\text{O}$ ($\text{M} + \text{H}$) $^+$ 196.1450, found 196.1450.



(S)-1-Diazo-3-((1-phenylethyl)amino)propan-2-one (3g). Yellow oil (93%); ^1H NMR (400 MHz, CDCl_3) δ 7.39 – 7.20 (m, 5H), 5.49 (s, 1H), 3.75 (q, J = 6.6 Hz, 1H), 3.25 (s, 2H), 1.90 (s, 1H), 1.37 (d, J = 6.6 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 194.7, 144.8, 128.7, 127.4, 126.8, 58.2, 55.1, 53.2, 24.4; IR (neat, cm^{-1}): 1143, 1349, 1638, 2104, 2967; $[\alpha]_D^{25}$ = -82.4 (c = 1.09 in CHCl_3); HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{14}\text{N}_3\text{O}$ ($\text{M} + \text{H}$) $^+$ 204.1137, found 204.1132.




1-((2-(1H-Indol-3-yl)ethyl)amino)-3-diazopropan-2-one (3h). Yellow oil (73%); ^1H NMR (400 MHz, CDCl_3) δ 8.18 (s, 1H), 7.62 (d, J = 7.8 Hz, 1H), 7.36 (d, J = 8.1 Hz, 1H), 7.30 – 7.08 (m, 2H), 7.04 (s, 1H), 5.60 (s, 1H), 3.39 (s, 2H), 3.27 – 2.91 (m, 4H), 1.72 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 195.4, 136.5, 127.5, 122.2, 122.1, 119.4, 118.9, 113.7, 111.3, 57.2, 53.0, 50.0, 26.0; IR (neat, cm^{-1}): 1147, 1342, 1634, 2105, 2918; HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{15}\text{N}_4\text{O}$ ($\text{M} + \text{H}$) $^+$ 243.1246, found 243.1239.

3. General procedure for the preparation of enamines.²


The amino diazoketone (0.20 mmol) was reacted with an alkyne (0.24 mmol, 1.2 equiv) in ethanol (1 mL) at ambient temperature overnight.^{3,4} Upon evaporation, the reaction mixture was treated

with the Ag catalyst (0.04 mmol, 20 mmol%) in CH₂Cl₂ (1 mL) at ambient temperature overnight, during which the flask was covered with aluminum foil to exclude light. This mixture was then washed with aq. NaHCO₃ and brine, dried over MgSO₄ and concentrated *in vacuo*. The crude mixture was subjected to column chromatography (MeOH/CH₂Cl₂), affording a desired enaminone.


PhCO₂Ag was used as a catalyst for the Wolff rearrangement in all cases except for the synthesis of enaminone **2c**, **4c**, **5c**, **5e** and **8a-c**, where Ag₂O was used instead.




Ethyl 1-Ethyl-4-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate (2b). White solid (85%); mp: 45.8-47.3 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.16 (s, 1H), 4.24 (q, *J* = 7.1 Hz, 2H), 3.60 – 3.41 (t, *J* = 7.5 Hz, 2H), 3.49 – 3.43 (q, *J* = 7.3 Hz, 2H), 2.59 – 2.50 (t, *J* = 7.8 Hz, 2H), 1.32 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 186.5, 165.6, 158.9, 100.5, 60.0, 52.1, 46.2, 36.1, 14.7, 14.0; IR (neat, cm⁻¹): 1053, 1159, 1246, 1303, 1335, 1398, 1605, 1714, 2978; HRMS (ESI) calcd for C₁₀H₁₆N₁O₃ (M + H)⁺ 198.1130, found 198.1124.




Ethyl 4-Oxo-1-propyl-1,4,5,6-tetrahydropyridine-3-carboxylate (2c). Off-white solid (88%); mp: 55.8-57.8 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.13 (s, 1H), 4.24 (q, *J* = 7.1 Hz, 2H), 3.59 – 3.48 (t, *J* = 7.5 Hz, 2H), 3.36 (t, *J* = 7.1 Hz, 2H), 2.60 – 2.47 (t, *J* = 7.5 Hz, 2H), 1.76 – 1.66 (m, 2H), 1.31 (t, *J* = 7.1 Hz, 3H), 0.97 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 186.5, 165.6, 159.5, 100.3, 60.0, 59.1, 46.5, 36.1, 21.7, 14.7, 11.0; IR (neat, cm⁻¹): 1054, 1157, 1240, 1301, 1333, 1384, 1459, 1602, 1658, 1719, 2966; HRMS (ESI) calcd for C₁₁H₁₈N₁O₃ (M + H)⁺ 212.1287, found 212.1290.




Ethyl 1-Allyl-4-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate (2d). Yellow oil (76%); ¹H NMR (400 MHz, CDCl₃) δ 8.15 (s, 1H), 5.84 (dq, *J* = 10.8, 6.0 Hz, 1H), 5.36 (m, 2H), 4.24 (q, *J* = 7.1 Hz, 2H), 3.98 (d, *J* = 6.0 Hz, 2H), 3.53 (t, *J* = 7.7 Hz, 2H), 2.54 (t, *J* = 7.7 Hz, 2H), 1.30 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 186.5, 165.5, 159.4, 131.3, 120.7, 100.9, 60.00, 59.58, 46.4, 36.1, 14.7; IR (neat, cm⁻¹): 1053, 1152, 1241, 1303, 1338, 1397, 1602, 1645, 1715, 2978; HRMS (ESI) calcd for C₁₁H₁₆N₁O₃ (M + H)⁺ 210.1130, found 210.1130.




Ethyl 1-Butyl-4-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate (2e). Clear oil (78%); ¹H NMR (400 MHz, CDCl₃) δ 8.12 (s, 1H), 4.25 (q, *J* = 7.1 Hz, 2H), 3.59 – 3.48 (t, *J* = 7.8 Hz, 2H), 3.39 (t, *J* = 7.2 Hz, 2H), 2.60 – 2.48 (t, *J* = 7.8 Hz, 2H), 1.71 – 1.57 (m, 2H), 1.42 – 1.29 (m, 5H), 0.98 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 186.4, 165.7, 159.5, 100.4, 60.0, 57.2, 46.6, 36.2, 30.5, 20.0, 14.7, 13.7; IR (neat, cm⁻¹): 1054, 1158, 1245, 1302, 1335, 1395, 1462, 1603, 1659, 1714, 2960; HRMS (ESI) calcd for C₁₂H₂₀N₁O₃ (M + H)⁺ 226.1443, found 226.1432.




Ethyl 1-(Cyclohexylmethyl)-4-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate (2f). Off-white solid (88%); mp: 65.1-66.5 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.07 (s, 1H), 4.24 (q, $J = 7.1$ Hz, 2H), 3.61 – 3.48 (t, $J = 7.6$ Hz, 2H), 3.20 (d, $J = 6.9$ Hz, 2H), 2.61 – 2.47 (t, $J = 7.6$ Hz, 2H), 1.83 – 1.61 (m, 7H), 1.36 – 1.11 (m, 5H), 0.94 (q, $J = 11.2$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 186.4, 165.67, 159.8, 100.1, 64.0, 60.0, 47.2, 36.8, 36.1, 30.6, 26.3, 25.7, 14.7; IR (neat, cm^{-1}): 1055, 1158, 1249, 1306, 1331, 1403, 1451, 1603, 1709, 2927; HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{24}\text{N}_1\text{O}_3$ ($\text{M} + \text{H}$) $^+$ 266.1756, found 266.1766.




Diethyl 1-Ethyl-4-oxo-1,4,5,6-tetrahydropyridine-2,3-dicarboxylate (4b). Yellow oil (90%); ^1H NMR (400 MHz, CDCl_3) δ 4.41 (q, $J = 7.2$ Hz, 2H), 4.23 (q, $J = 7.1$ Hz, 2H), 3.63 (t, $J = 7.5$ Hz, 2H), 3.39 (q, $J = 7.1$ Hz, 2H), 2.55 (t, $J = 7.5$ Hz, 2H), 1.38 (t, $J = 7.2$ Hz, 3H), 1.30 (m, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 186.9, 165.5, 163.6, 160.4, 100.3, 62.8, 60.6, 49.4, 47.5, 35.8, 14.5, 13.99, 13.96; IR (neat, cm^{-1}): 1050, 1157, 1256, 1379, 1449, 1555, 1666, 1740, 2982; HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{20}\text{N}_1\text{O}_5$ ($\text{M} + \text{H}$) $^+$ 270.1341, found 270.1330.




Diethyl 4-Oxo-1-propyl-1,4,5,6-tetrahydropyridine-2,3-dicarboxylate (4c). Clear oil (81%); ^1H NMR (400 MHz, CDCl_3) δ 4.39 (q, $J = 7.2$ Hz, 2H), 4.21 (q, $J = 7.1$ Hz, 2H), 3.67 – 3.57 (t, $J = 7.4$ Hz, 2H), 3.31 – 3.22 (t, $J = 7.6$ Hz, 2H), 2.59 – 2.48 (t, $J = 7.4$ Hz, 2H), 1.77 – 1.65 (m, 2H), 1.37 (t, $J = 7.2$ Hz, 3H), 1.29 (t, $J = 7.1$ Hz, 3H), 0.93 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 186.9, 165.5, 163.6, 160.6, 100.3, 62.8, 60.5, 55.9, 47.9, 35.8, 22.0, 14.5, 14.0, 11.06; IR (neat, cm^{-1}): 1023, 1071, 1175, 1254, 1299, 1378, 1448, 1552, 1668, 1740, 2978; HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{22}\text{N}_1\text{O}_5$ ($\text{M} + \text{H}$) $^+$ 284.1498, found 284.1496.




Diethyl 1-Allyl-4-oxo-1,4,5,6-tetrahydropyridine-2,3-dicarboxylate (4d). Yellow oil (quant.); ^1H NMR (400 MHz, CDCl_3) δ 5.82 (ddt, $J = 16.5, 10.4, 6.1$ Hz, 1H), 5.38 – 5.29 (m, 2H), 4.39 (q, $J = 7.2$ Hz, 2H), 4.23 (q, $J = 7.1$ Hz, 2H), 3.90 (d, $J = 6.1$ Hz, 2H), 3.63 – 3.55 (t, $J = 7.5$ Hz, 2H), 2.58 – 2.51 (t, $J = 7.5$ Hz, 2H), 1.37 (t, $J = 7.2$ Hz, 3H), 1.30 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 187.0, 165.4, 163.6, 160.3, 131.2, 120.7, 100.2, 62.9, 60.7, 56.5, 47.6, 35.8, 14.5, 14.0; IR (neat, cm^{-1}): 1025, 1074, 1176, 1255, 1378, 1448, 1551, 1669, 1740, 2981; HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{20}\text{N}_1\text{O}_5$ ($\text{M} + \text{H}$) $^+$ 282.1341, found 282.1349.




Diethyl 1-Butyl-4-oxo-1,4,5,6-tetrahydropyridine-2,3-dicarboxylate (4e). Clear oil (93%); ^1H NMR (400 MHz, CDCl_3) δ 4.40 (q, $J = 7.2$ Hz, 2H), 4.22 (q, $J = 7.1$ Hz, 2H), 3.68 – 3.58 (t, $J = 7.5$ Hz, 2H), 3.36 – 3.26 (t, $J = 7.7$ Hz, 2H), 2.58 – 2.49 (t, $J = 7.5$ Hz, 2H), 1.68 (m, 2H), 1.41 – 1.27 (m, 8H), 0.95 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 186.9, 165.5, 163.6, 160.5, 100.4, 62.8, 60.6, 54.2, 48.0, 35.8, 30.8, 20.0, 14.5, 14.0, 13.8; IR (neat, cm^{-1}): 1025, 1072, 1175, 1254, 1378, 1459, 1554, 1668, 1741, 2961; HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{24}\text{N}_1\text{O}_5$ ($\text{M} + \text{H}$) $^+$ 298.1654, found 298.1646.




Diethyl 1-(Cyclohexylmethyl)-4-oxo-1,4,5,6-tetrahydropyridine-2,3-dicarboxylate (4f). Yellow oil (86%); ^1H NMR (400 MHz, CDCl_3) δ 4.38 (q, $J = 7.2$ Hz, 2H), 4.22 (q, $J = 7.1$ Hz, 2H), 3.68 – 3.57 (t, $J = 7.4$ Hz, 2H), 3.16 (d, $J = 6.9$ Hz, 2H), 2.57 – 2.48 (t, $J = 7.4$ Hz, 2H), 1.81 – 1.66 (m, 6H), 1.37 (t, $J = 7.2$ Hz, 3H), 1.30 (t, $J = 7.1$ Hz, 3H), 1.27 – 1.11 (m, 3H), 0.92 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 187.0, 165.6, 163.5, 160.7, 100.6, 62.8, 60.6, 60.2, 48.6, 37.5, 35.8, 30.9, 26.2, 25.8, 14.5, 14.0; IR (neat, cm^{-1}): 1154, 1246, 1378, 1449, 1547, 1668, 1740, 2927; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{28}\text{N}_1\text{O}_5$ ($\text{M} + \text{H}$) $^+$ 338.1967, found 338.1970.




5-Acetyl-1-ethyl-2,3-dihydropyridin-4(1H)-one (5b). White solid (94%); mp: 55.0-57.4 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 8.27 (s, 1H), 3.61 – 3.55 (t, $J = 7.7$ Hz, 2H), 3.49 (q, $J = 7.3$ Hz, 2H), 2.59 – 2.52 (t, $J = 7.7$ Hz, 2H), 2.49 (s, 3H), 1.34 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 195.3, 188.0, 158.7, 110.0, 52.3, 46.5, 36.0, 30.6, 13.9; IR (neat, cm^{-1}): 1150, 1248, 1324, 1360, 1388, 1586, 1634, 2975; HRMS (ESI) calcd for $\text{C}_9\text{H}_{14}\text{N}_1\text{O}_2$ ($\text{M} + \text{H}$) $^+$ 168.1025, found 168.1021.




5-Acetyl-1-propyl-2,3-dihydropyridin-4(1H)-one (5c). White solid (84%); mp: 81.3-83.8 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 8.24 (s, 1H), 3.62 – 3.51 (t, $J = 7.7$ Hz, 2H), 3.40 (t, $J = 7.1$ Hz, 2H), 2.58 – 2.52 (t, $J = 7.7$ Hz, 2H), 2.50 (s, 3H), 1.79 – 1.66 (m, 2H), 0.97 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 195.3, 188.0, 159.3, 109.8, 59.2, 46.8, 36.0, 30.6, 21.7, 11.0; IR (neat, cm^{-1}): 1150, 1246, 1325, 1394, 1595, 1626, 2965; HRMS (ESI) calcd for $\text{C}_{10}\text{H}_{16}\text{N}_1\text{O}_2$ ($\text{M} + \text{H}$) $^+$ 182.1181, found 182.1174.




5-Acetyl-1-allyl-2,3-dihydropyridin-4(1H)-one (5d). White solid (90%); mp: 42.5-44.0 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.25 (s, 1H), 5.84 (ddt, J = 16.4, 10.2, 6.1 Hz, 1H), 5.43 – 5.30 (m, 2H), 4.01 (d, J = 6.1 Hz, 2H), 3.55 (t, J = 7.7 Hz, 2H), 2.58 – 2.52 (t, J = 7.7 Hz, 2H), 2.49 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 195.3, 188.1, 159.2, 131.0, 121.0, 110.3, 59.8, 46.6, 36.0, 30.6; IR (neat, cm^{-1}): 1148, 1237, 1323, 1361, 1388, 1583, 1635, 2922; HRMS (ESI) calcd for $\text{C}_{10}\text{H}_{14}\text{N}_1\text{O}_2$ ($\text{M} + \text{H}$) $^+$ 180.1025, found 180.1022.




5-Acetyl-1-butyl-2,3-dihydropyridin-4(1H)-one (5e). Off-white solid (81%); mp: 60.4-62.2 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.24 (s, 1H), 3.56 (t, J = 7.7 Hz, 2H), 3.42 (t, J = 7.2 Hz, 2H), 2.54 (t, J = 7.7 Hz, 2H), 2.49 (s, 3H), 1.75 – 1.53 (m, 2H), 1.36 (m, 2H), 0.97 (t, J = 7.3 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 195.2, 188.0, 159.2, 109.8, 57.4, 46.8, 36.0, 30.6, 30.4, 19.8, 13.7; IR (neat, cm^{-1}): 1153, 1328, 1359, 1395, 1595, 1623, 2958; HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{18}\text{N}_1\text{O}_2$ ($\text{M} + \text{H}$) $^+$ 196.1338, found 196.1331.




5-Acetyl-1-(cyclohexylmethyl)-2,3-dihydropyridin-4(1H)-one (5f). Off-white solid (92%); mp: 124.8-126.0 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.18 (s, 1H), 3.61 – 3.51 (t, J = 7.7 Hz, 2H), 3.23 (d, J = 6.9 Hz, 2H), 2.57 – 2.51 (t, J = 7.7 Hz, 2H), 2.49 (s, 3H), 1.82 – 1.63 (m, 6H), 1.32 – 1.10 (m, 3H), 0.94 (q, J = 12.4 Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 195.3, 188.4, 159.6, 109.7, 64.1, 47.5, 36.7, 36.0, 30.6 (overlap of two non-equivalent carbons), 26.2, 25.7; IR (neat, cm^{-1}): 1152, 1249, 1324, 1362, 1388, 1451, 1584, 1634, 2925; HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{22}\text{N}_1\text{O}_2$ ($\text{M} + \text{H}$) $^+$ 236.1651, found 236.1653.




5-Benzoyl-1-ethyl-2,3-dihydropyridin-4(1H)-one (6b). Off-white solid (81%); mp: 89.5-91.4 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.12 (s, 1H), 7.67 – 7.59 (m, 2H), 7.48 – 7.41 (m, 1H), 7.37 (t, J = 7.4 Hz, 2H), 3.69 – 3.61 (t, J = 7.7 Hz, 2H), 3.53 (q, J = 7.2 Hz, 2H), 2.64 – 2.53 (t, J = 7.7 Hz, 2H), 1.37 (t, J = 7.3 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.6, 186.7, 159.1, 140.5, 131.3, 129.0, 127.7, 110.1, 52.2, 46.4, 35.9, 14.0; IR (neat, cm^{-1}): 1191, 1252, 1325, 1384, 1447, 1587, 1623, 2975; HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{16}\text{N}_1\text{O}_2$ ($\text{M} + \text{H}$) $^+$ 230.1181, found 230.1179.




1-Allyl-5-benzoyl-2,3-dihydropyridin-4(1H)-one (6c). Off-white solid (63%); mp: 88.1-89.9 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.10 (s, 1H), 7.63 (m, 2H), 7.49 – 7.42 (m, 1H), 7.37 (m, 2H), 5.89 (ddt, *J* = 16.4, 10.2, 6.1 Hz, 1H), 5.40 (m, 2H), 4.03 (d, *J* = 6.1 Hz, 2H), 3.62 (t, *J* = 7.7 Hz, 2H), 2.60 (t, *J* = 7.7 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 192.7, 186.9, 159.6, 140.3, 131.4, 131.1, 129.0, 127.7, 121.0, 110.5, 59.8, 46.6, 35.8; IR (neat, cm⁻¹): 1190, 1239, 1323, 1385, 1585, 1623, 2923; HRMS (ESI) calcd for C₁₅H₁₆N₁O₂ (M + H)⁺ 242.1181, found 242.1173.




5-Benzoyl-1-(cyclohexylmethyl)-2,3-dihydropyridin-4(1H)-one (6d). Off-white solid (88%); mp: 152.4-154.5 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.03 (s, 1H), 7.69 – 7.59 (m, 2H), 7.48 – 7.41 (m, 1H), 7.40 – 7.33 (m, 2H), 3.62 (t, *J* = 7.6 Hz, 2H), 3.26 (d, *J* = 6.9 Hz, 2H), 2.63 – 2.52 (t, *J* = 7.6 Hz, 2H), 1.86 – 1.64 (m, 6H), 1.35 – 1.12 (m, 3H), 1.04 – 0.89 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 192.6, 186.8, 160.1, 140.5, 131.3, 129.0, 127.7, 109.7, 64.1, 47.5, 36.8, 35.9, 30.7, 26.3, 25.7; IR (neat, cm⁻¹): 1191, 1254, 1322, 1385, 1449, 1584, 1622, 2925; HRMS (ESI) calcd for C₁₉H₂₄N₁O₂ (M + H)⁺ 298.1807, found 298.1804.




(S)-Ethyl 4-Oxo-1-(1-phenylethyl)-1,4,5,6-tetrahydropyridine-3-carboxylate (7a). Yellow oil (86%); ¹H NMR (400 MHz, CDCl₃) δ 8.45 (s, 1H), 7.45 – 7.33 (m, 3H), 7.30 – 7.26 (m, 2H), 4.71 (q, *J* = 7.0 Hz, 1H), 4.28 (q, *J* = 7.1 Hz, 2H), 3.48 – 3.36 (m, 1H), 3.35 – 3.26 (m, 1H), 2.43 (m, 2H), 1.72 (d, *J* = 7.0 Hz, 3H), 1.34 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 186.7, 165.9, 157.3, 138.8, 129.4, 128.9, 126.5, 100.8, 64.6, 60.1, 44.6, 36.2, 19.2, 14.7; IR (neat, cm⁻¹): 1052, 1140, 1245, 1297, 1394, 1456, 1595, 1659, 1717, 2978; [α]_D = -17 (*c* = 0.99 in CHCl₃); HRMS (ESI) calcd for C₁₆H₂₀N₁O₃ (M + H)⁺ 274.1443, found 274.1435.




(S)-Diethyl 4-Oxo-1-(1-phenylethyl)-1,4,5,6-tetrahydropyridine-2,3-dicarboxylate (7b). Yellow oil (67%); ¹H NMR (400 MHz, CDCl₃) δ 7.49 – 7.31 (m, 5H), 4.94 (q, *J* = 6.8 Hz, 1H), 4.54 – 4.41 (m, 2H), 4.32 – 4.20 (m, 2H), 3.40 (ddd, *J* = 13.6, 10.4, 5.8 Hz, 1H), 3.16 (ddd, *J* = 13.5, 7.5, 5.9 Hz, 1H), 2.40 – 2.21 (m, 2H), 1.70 (d, *J* = 6.9 Hz, 3H), 1.40 (t, *J* = 7.2 Hz, 3H), 1.32 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 187.2, 165.7, 164.1, 160.2, 137.5, 129.2, 128.9, 127.3, 100.4, 63.0, 60.6, 60.0, 42.1, 35.8, 16.5, 14.5, 14.1; IR (neat, cm⁻¹): 1026, 1142, 1255, 1299, 1374, 1453, 1538, 1668, 1738, 2982; [α]_D = -26 (*c* = 0.97 in CHCl₃); HRMS (ESI) calcd for C₁₉H₂₄N₁O₅ (M + H)⁺ 346.1654, found 346.1642.




(S)-5-Acetyl-1-(1-Phenylethyl)-2,3-dihydropyridin-4(1H)-one (7c). Yellow oil (75%); ^1H NMR (400 MHz, CDCl_3) δ 8.57 (s, 1H), 7.46 – 7.32 (m, 3H), 7.30 – 7.26 (m, 2H), 4.74 (q, $J = 7.0$ Hz, 1H), 3.51 – 3.37 (m, 1H), 3.37 – 3.24 (m, 1H), 2.52 (s, 3H), 2.43 (m, 2H), 1.72 (d, $J = 7.0$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 195.5, 188.3, 157.0, 138.6, 129.4, 128.9, 126.6, 110.2, 65.0, 44.8, 36.0, 30.7, 19.2; IR (neat, cm^{-1}): 1051, 1141, 1248, 1292, 1574, 1635, 2978; $[\alpha]_{\text{D}} = -19$ ($c = 0.95$ in CHCl_3); HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{18}\text{N}_1\text{O}_2$ ($\text{M} + \text{H}$) $^+$ 244.1338, found 244.1338.




(S)-5-Benzoyl-1-(1-phenylethyl)-2,3-dihydropyridin-4(1H)-one (7d). Yellow oil (81%); ^1H NMR (400 MHz, CDCl_3) δ 8.41 (s, 1H), 7.69 – 7.61 (m, 2H), 7.46 – 7.30 (m, 8H), 4.77 (q, $J = 7.0$ Hz, 1H), 3.55 – 3.45 (m, 1H), 3.45 – 3.35 (m, 1H), 2.48 (m, 2H), 1.75 (d, $J = 7.0$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.8, 187.1, 157.5, 140.4, 138.7, 131.4, 129.4, 129.0, 129.0, 127.7, 126.6, 110.3, 64.9, 44.8, 35.9, 19.2; IR (neat, cm^{-1}): 1080, 1186, 1252, 1296, 1345, 1378, 1455, 1581, 1622, 2980; $[\alpha]_{\text{D}} = -13$ ($c = 0.98$ in CHCl_3); HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{20}\text{N}_1\text{O}_2$ ($\text{M} + \text{H}$) $^+$ 306.1494, found 306.1479.



Ethyl 1-(2-(1H-Indol-3-yl)ethyl)-4-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate (8a). White solid (76%); mp: 157.5–158.5 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 8.36 (s, 1H), 7.91 (s, 1H), 7.56 (d, $J = 7.9$ Hz, 1H), 7.41 (d, $J = 8.1$ Hz, 1H), 7.23 (m, 1H), 7.15 (t, $J = 7.1$ Hz, 1H), 7.02 (d, $J = 2.0$ Hz, 1H), 4.16 (q, $J = 7.1$ Hz, 2H), 3.72 (t, $J = 6.7$ Hz, 2H), 3.49 (t, $J = 7.7$ Hz, 2H), 3.14 (t, $J = 6.7$ Hz, 2H), 2.48 – 2.38 (t, $J = 7.6$ Hz, 2H), 1.23 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 186.7, 165.3, 159.5, 136.6, 126.7, 122.9, 122.7, 120.0, 118.2, 111.9, 110.8, 100.2, 60.0, 57.6, 47.2, 36.1, 25.3, 14.6; IR (neat, cm^{-1}): 1054, 1157, 1243, 1338, 1400, 1457, 1602, 1709, 3286; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{21}\text{N}_2\text{O}_3$ ($\text{M} + \text{H}$) $^+$ 313.1552, found 313.1541.



Diethyl 1-(2-(1H-Indol-3-yl)ethyl)-4-oxo-1,4,5,6-tetrahydropyridine-2,3-dicarboxylate (8b). Off-white solid (73%); mp: 46.9–48.8 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 8.15 (s, 1H), 7.59 (d, $J = 7.8$ Hz, 1H), 7.40 (d, $J = 8.1$ Hz, 1H), 7.25 – 7.20 (m, 1H), 7.16 (m, 1H), 7.06 (d, $J = 2.0$ Hz, 1H), 4.30 (q, $J = 7.2$ Hz, 2H), 4.23 (q, $J = 7.1$ Hz, 2H), 3.72 – 3.62 (m, 2H), 3.57 – 3.48 (t, $J = 7.5$ Hz, 2H), 3.16 (t, $J = 7.3$ Hz, 2H), 2.42 – 2.30 (m, 2H), 1.31 (m, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 187.2, 165.5, 163.7, 160.4, 136.5, 127.0, 122.7, 122.6, 120.0, 118.4, 111.7, 111.3, 100.7, 62.9, 60.6, 54.9, 49.0, 35.7, 25.6, 14.5, 14.0; IR (neat, cm^{-1}): 1028, 1174, 1257, 1378, 1458, 1552, 1658, 1714, 1739, 3306; HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{25}\text{N}_2\text{O}_5$ ($\text{M} + \text{H}$) $^+$ 385.1763, found 385.1747.



1-(2-(1H-Indol-3-yl)ethyl)-5-acetyl-2,3-dihydropyridin-4(1H)-one (8c). Off-white solid (61%); mp: 183.7-184.3 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.24 (s, 1H), 8.15 (s, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.23 (t, J = 7.6 Hz, 1H), 7.16 (m, 1H), 7.02 (d, J = 2.0 Hz, 1H), 3.73 (t, J = 7.0 Hz, 2H), 3.50 (t, J = 7.7 Hz, 2H), 3.15 (t, J = 6.9 Hz, 2H), 2.47 (s, 3H), 2.45 – 2.39 (t, J = 7.7 Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 195.2, 188.1, 159.2, 136.5, 126.8, 122.8, 122.5, 120.0, 118.2, 111.8, 111.0, 109.9, 57.8, 47.5, 36.0, 30.6, 25.4; IR (neat, cm^{-1}): 1151, 1323, 1361, 1583, 1629, 2924, 3282; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{19}\text{N}_2\text{O}_2$ ($\text{M} + \text{H}$) $^+$ 283.1447, found 283.1450.

4. References and notes

1. Bromo diazoacetone was synthesized according to the literature: Padwa, A.; Austin, D. J.; Precedo, L.; Zhi, L. *J. Org. Chem.*, **1993**, *58*, 1144.

2. Products **2a**, **4a**, **5a** and **6a** have been reported by us: Seki, H.; Georg, G. I. *J. Am. Chem. Soc.* **2010**, *132*, 15512.

3. All amino diazoketones were carried to the next reaction immediately after isolation because they are not stable over a long period of time.

4. 1-Phenylprop-2-yn-1-one used for the synthesis of enaminones **6** was prepared using a reported method: Chassaing, S.; Kueny-Stotz, M.; Isorez, G.; Brouillard, R. *Eur. J. Org. Chem.* **2007**, 2438.